【レポートの概要（一部）】
1. Report Overview
1. Executive Summary
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.4 Biomarkers to Companion Diagnostics
2.3.5 Genomic Biomarkers
2.3.6 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2015-2025
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014
3.3 The Global Companion Diagnostics Market Sales Forecast, 2015-2025
3.4 Companion Diagnostics: Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Will Outpace the Rest of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025
4. Leading National Markets for Companion Diagnostics, 2015-2025
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2015-2025
4.2.1 Changing Market Shares of Leading National Markets, 2015-2025
4.3 The US Companion Diagnostics Market Sales Forecast, 2015-2025
4.3.1 The U.S Will Continue to Dominate the Market
4.3.2 Leading Companion Diagnostics U.S Companies
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2015-2025
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2015-2025
4.5.1 Japan’s Slow Medical Technology Regulatory Process
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2015-2025
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic tests
4.6.2 Ventana: A Major Player Moving into China’s Companion Diagnostics Space
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2015-2025
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2015-2025
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2015-2025
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2015-2025
4.11 The Mexican Companion Diagnostics Market Sales Forecast, 2015-2025
4.12 The Rest of the World Companion Diagnostics Market Sales Forecast, 2015-2025
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships Market
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 U.S FDA Approved Companion Diagnostic Tests, 2015
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Other Disease Indication Opportunities in the Companion Diagnostics Market
5.6 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Large Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2015
7. Leading Companies in the Companion Diagnostics Market
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Companion Diagnostic Project Pipeline
7.1.7 Roche’s Portfolio of Marketed Companion Diagnostics, 2015
7.1.8 Ventana Companion Diagnostics: New Robust Prototype Assays
7.1.9 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.9.1 Ventana/Genmab
7.1.9.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.9.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.9.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.9.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.9.6 Boehringer Ingelheim/Roche
7.1.9.7 ImmunoGene/ Ventana
7.1.9.8 Foundation Medicine/Roche
7.1.9.9 Acquisitions: Bolstering their Genomic-based Diagnostic Technologies
7.2 Qiagen: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2013-2014
7.2.1.1 Sales and Recent Performance Analysis, Q1-Q3 2014
7.2.2 Companion Diagnostics Collaboration Agreements with Pharma, 2014
7.2.2.1 Collaboration with Eli Lilly
7.2.2.2 Collaboration with AstraZeneca
7.2.2.3 Collaboration with Astellas Pharma
7.2.2.4 Collaboration with Novartis
7.2.2.5 Collaborative Agreements with Technology Companies, 2014
7.2.2.5.1 Collaboration with Protagen
7.2.3 Qiagen: CDx Portfolio and Pipeline
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2013-2014
7.3.1.1 Sales and Recent Performance Analysis, Q1-Q3 2014
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.4 Dako (Agilent)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and recent Performance Analysis, 2014
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 BART Test: A High Revenue Generating Product
7.5.3.2 Sales and Recent Performance, Q1-Q3 2014
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2013-2014
7.6.2 Sales by Region, 2013
7.6.3 Sales and Recent Performance Analysis, Q1-Q3, 2014
7.6.4 FDA Approval for Metastatic Melanoma Companion Diagnostic Test
7.6.5 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.5.1 Collaboration Gilead Sciences
7.6.5.2 Collaboration with Ipsen
7.6.5.3 Collaboration with Merck
7.7 Siemens Diagnostics
7.7.1 Siemens Diagnostics: Sales and Recent Performance Analysis, 2013-2014
7.7.2 Siemens Healthcare Research and Development for Diagnostics
7.7.3 Recent Companion Diagnostics Partnerships
7.7.3.1 Agreement with Pfizer
7.7.3.2 Collaboration with Janssen Pharmaceutical
7.7.3.3 Partnership with ViiV Healthcare
7.7.3.4 Partnership with Tocagen
7.7.3.5 Siemens Healthcare: An Uncertain Future
7.8 Thermo Fisher Scientific
7.8.1 Sales and Recent Performance Analysis, 2013-2014
7.8.1.1 Sales Performance by Region, 2013
7.8.1.2 Thermo Fisher Scientific Financial Performance, Q1-3Q 2014
7.8.2 Recent Collaborations and Acquisitions
7.8.2.1 Acquisition of Life Technologies
7.8.2.2 Acquisition of Prionics
7.8.2.3 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.8.2.4 Thermo Fisher Life Technologies Collaborates with Merck Serono
7.9 Lab 21: Fast Grower in Companion Diagnostics
7.9.1 Partnership with IntegraGen
7.9.2 Partnership with an Undisclosed Major Pharmaceutical Company
7.9.3 Lab 21: A Forerunner in Offering FDA approved Companion Diagnostics
7.9.4 New Lung Cancer Companion Diagnostic Service
8. Quantitative Analysis of the Companion Diagnostics Market, 2015-2025
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy can Generate more Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Target Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges and Undervalue
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Full Oncology Pipeline and Other Drug Categories will Benefit from CDx
8.4.4 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s 5 Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Expert Opinions
9.1 Interview with Dr Philip D. Cotter, Principal and Co-Founder of ResearchDx, and Laboratory Director of Pacific Diagnostics Clinical Laboratory, a subsidiary of ResearchDx
9.1.1 Contract Diagnostics: A Growing Industry
9.1.2 Identifying Companion Diagnostic Partners During the Drug Development Phase
9.1.3 Oncology is Still the Largest Category for Companion Diagnostics
9.1.4 Timing the CDx/Drug Development Phase is Key to Success
9.1.5 Companion Diagnostics: A Faster Route to Therapy Approval
9.1.6 Next Generation Sequencing: A Necessary Technology?
9.2 Professor Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research
9.2.1 Companion Diagnostics: Also Known as Predictive Biomarkers
9.2.2 Oncology: A Promising Pipeline of Targeted Therapies
9.2.3 Technological Platforms for Biomarker Discovery
9.2.4 Cancer Targets: Some are More Challenging than Others
9.2.5 Beyond Oncology: Biomarkers could Aid Infectives
9.2.6 The Challenges of Heterogeneous Cancers
9.2.7 Cancer Research UK Drug Discovery Programme
10. Conclusion
10.1 Overview
10.2 Theranostics: A Fast Growing Market
10.3 Leading Companion Diagnostic Companies
10.4 Pharmaceutical/Diagnostic Partnership Model
10.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
10.6 Commercial Drivers of the Companion Diagnostics Market
10.7 Commercial Restraints of the Companion Diagnostics Market
10.8 Concluding Remarks
【レポート販売概要】
■ タイトル：コンパニオン診断（CDx）の世界市場■ 英文：The Companion Diagnostics (CDx) Market Forecast 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN502206
■ 調査対象地域：グローバル
- Lukoil Oil Company：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Lukoil Oil Company Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Lukoil Oil Company Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for k …
- リニアモーションシステムの世界市場About Linear Motion SystemsLinear motion system is a device used for motion of a component in XY direction. This is used in packaging and machine tools, palletizing, robotics, and material handling equipment. Technavio’s analysts forecast the global linear motion systems market to grow at a CAGR of 7.62% during the period 2017-2021. [Covered in this report] The report covers the present scenario a …
- 強迫性障害(Obsessive-Compulsive Disorder)の治療薬パイプライン動向（2015年上半期版）Obsessive-Compulsive Disorder - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H1 2015’, provides an overview of the Obsessive-Compulsive Disorder’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, t …
- 血液及びフローサイトメトリー検査のグローバル市場Complete report $24,500. DataPack (test volumes, sales forecasts, supplier shares) $15,900. “Hematology and Flow Cytometry: A Market Facing Regulatory and Competitive Challenges--Advances in Molecular Diagnostics, IT, and Growing Understanding of Immunologic Forces Regulating Systemic Diseases Will Profoundly Impact the Market” is Venture Planning Group’s new seven-cou …
- エレクトリック・ギターの世界市場2016-2020About Electric Guitar An electric guitar is built with a transducer to magnify vibrations of the guitar strings. When the guitar is plugged into an amplifier, the electrical signals generated are boosted by an audio-frequency amplifier and sent to a loudspeaker. The volume and resonance of the guitar are controlled by the player. Special effects such as reverb and distortion can also be generated …
- 世界のエルシニア検査市場The report presents a detailed analysis of the Yersinia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Yersinia definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Commer …
- アレルゲン免疫療法（allergic immunotherapies）：ワクチンのグローバル市場機会分析Allergy or Allergic rhinitis is caused by sensitivity to a number of environmental factors including grass, tree and weed pollens, house dust mite and cat dander. Prevalence in adults can range from 17 - 40% and is region/climate dependent. For those patients failing to respond to symptomatic treatments e.g. antihistamines Allergen-specific immunotherapy can be an effective alternative which invol …
- 世界の小売業界における地理情報システム（GIS）市場：GISソフトウェア/データ/サービスAbout GIS A GIS is a system or a set of tools used to interpret business and geospatial data. It integrates hardware, software, and data for processing business and geographically referenced data. This system digitizes the received geospatial data and processes them to provide the desired output. GIS is used across sectors such as Natural Resources, Retail, Utilities, Federal Government, Communica …
- ダイボンダー設備の世界市場予測（～2024年）“Die bonder equipment market is projected to grow at CAGR of 3.5% from 2019 to 2024” The global die bonder equipment market size is projected to grow from USD 820 million in 2019 to USD 972 million by 2024, at a CAGR of 3.5% from 2019 to 2024. Key factors fueling the growth of this market include the growing demand for miniature electronic components and the increasing adoption of stacked die tech …
- 非血管ステントの世界市場分析および予測MediPoint: Non-Vascular Stents - Global Analysis and Market Forecasts Summary Non-vascular stent technology has evolved over the years such that these devices are routinely used in clinical practice for different indications. Although it is a mature market, both short and long-term complications associated with non-vascular stents continue to persist. This report focuses on four market categories …
- 世界主要国のクリプトスポリジウム検査（医療機器）市場The report presents a detailed analysis of the Cryptosporidium diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cryptosporidium definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- 世界の埋め込み型注入ポンプ市場：医療機器パイプライン分析2016Implantable Infusion Pumps - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Implantable Infusion Pumps - Medical Devices Pipeline Assessment, 2016" provides an overview of Implantable Infusion Pumps currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various …
- アフェクティブコンピューティングの世界市場予測：タッチベース、タッチレスDeployment of emotion AI-related technologies in customer interaction solutions across retail and healthcare verticals and growing adoption of virtual assistants for healthcare and entertainment purposes are driving the overall growth of the affective computing market.The global affective computing market size is projected to grow from USD 22.2 billion in 2019 to USD 90.0 billion by 2024, at a CAG …
- 重要インフラ防護（CIP）の世界市場予測2016-2026Our new study reveals trends, market progress, and predicted revenuesWhere is the CIP market heading? If you are involved in the critical infrastructure protection sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 378 page report provide …
- Google Capitalism EmergingGoogle has been the most successful Internet company to date, a cash-making machine, dominating the online advertising market. Offering a large variety of online services for free, Google promotes the “do no evil” mantra to portray themselves as a platform, next-generation corporation that can peacefully coexist with and serve the online society. However, Google has accumulated enough market share …
